Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TECLISTAMAB-CQYV: 1,592 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
1,592
Total FAERS Reports
338 (21.2%)
Deaths Reported
395
Hospitalizations
1,592
As Primary/Secondary Suspect
60
Life-Threatening
15
Disabilities
Prescription
Status

FDA Application: 761291 ·

First Report: 20201201 · Latest Report: 20250924

What Are the Most Common TECLISTAMAB-CQYV Side Effects?

#1 Most Reported
Cytokine release syndrome
406 reports (25.5%)
#2 Most Reported
Immune effector cell-associated neurotoxicity syndrome
153 reports (9.6%)
#3 Most Reported
Off label use
122 reports (7.7%)

All TECLISTAMAB-CQYV Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Cytokine release syndrome 406 25.5% 47 131
Immune effector cell-associated neurotoxicity syndrome 153 9.6% 43 67
Off label use 122 7.7% 19 29
Death 116 7.3% 116 15
Plasma cell myeloma 96 6.0% 47 22
Infection 83 5.2% 31 28
Neutropenia 74 4.7% 9 27
Fatigue 72 4.5% 8 20
Pyrexia 67 4.2% 5 23
Covid-19 64 4.0% 22 24
Pneumonia 58 3.6% 21 30
Drug ineffective 46 2.9% 5 5
Diarrhoea 39 2.5% 6 17
Thrombocytopenia 39 2.5% 10 13
Neuropathy peripheral 36 2.3% 2 5
Sepsis 36 2.3% 20 21
Anaemia 35 2.2% 5 11
Product dose omission issue 32 2.0% 0 0
Hypotension 28 1.8% 1 15
Nausea 28 1.8% 1 13

Who Reports TECLISTAMAB-CQYV Side Effects? Age & Gender Data

Gender: 49.5% female, 50.5% male. Average age: 68.9 years. Most reports from: US. View detailed demographics →

Is TECLISTAMAB-CQYV Getting Safer? Reports by Year

YearReportsDeathsHosp.
2020 6 0 0
2021 1 0 0
2022 22 6 9
2023 231 42 109
2024 199 24 84
2025 92 10 34

View full timeline →

What Is TECLISTAMAB-CQYV Used For?

IndicationReports
Plasma cell myeloma 853
Product used for unknown indication 536
Plasma cell myeloma refractory 164
Primary amyloidosis 7
Light chain disease 6
Plasma cell myeloma recurrent 6

TECLISTAMAB-CQYV vs Alternatives: Which Is Safer?

TECLISTAMAB-CQYV vs TEDIZOLID TECLISTAMAB-CQYV vs TEDUGLUTIDE TECLISTAMAB-CQYV vs TEDUGLUTIDE\WATER TECLISTAMAB-CQYV vs TEGAFUR TECLISTAMAB-CQYV vs TEGAFUR\URACIL TECLISTAMAB-CQYV vs TEGASEROD TECLISTAMAB-CQYV vs TEGRETOL TECLISTAMAB-CQYV vs TEICOPLANIN TECLISTAMAB-CQYV vs TELAPREVIR TECLISTAMAB-CQYV vs TELBIVUDINE

Official FDA Label for TECLISTAMAB-CQYV

Official prescribing information from the FDA-approved drug label.